Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 15c
February 14, 2018 4:03 PM ESTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.03, $0.15 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $44.3 million versus the consensus estimate of $43.45 million.
Sees combined net product sales from both HETLIOZ® and Fanapt® $180 to $200 million
For earnings history and... More
